Page last updated: 2024-12-11
isocryptomerin
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
isocryptomerin: an antifungal agent isolated from Selaginella tamariscina; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 5318537 |
| CHEMBL ID | 3589108 |
| SCHEMBL ID | 13485651 |
| MeSH ID | M0533222 |
Synonyms (14)
| Synonym |
|---|
| isocryptomerin |
| 6-[4-(5,7-dihydroxy-4-oxochromen-2-yl)phenoxy]-5-hydroxy-2-(4-hydroxyphenyl)-7-methoxychromen-4-one |
| 20931-58-2 |
| SCHEMBL13485651 |
| CHEMBL3589108 , |
| 6-[4-(5,7-dihydroxy-4-oxo-chromen-2-yl)phenoxy]-5-hydroxy-2-(4-hydroxyphenyl)-7-methoxy-chromen-4-one |
| isocyptomerin |
| 6-[4-(5,7-dihydroxy-4-oxo-4h-chromen-2-yl)phenoxy]-5-hydroxy-2-(4-hydroxyphenyl)-7-methoxy-4h-chromen-4-one |
| bdbm50522702 |
| XI161807 |
| HY-N11506 |
| lsocryptomerin |
| CS-0648281 |
| 6-(4-(5,7-dihydroxy-4-oxo-4h-chromen-2-yl)phenoxy)-5-hydroxy-2-(4-hydroxyphenyl)-7-methoxy-4h-chromen-4-one |
Research Excerpts
Overview
Isocryptomerin is a biflavonoid isolated from Selaginella tamariscina used in traditional medicine.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Isocryptomerin is a biflavonoid isolated from Selaginella tamariscina used in traditional medicine. " | ( Isocryptomerin, a novel membrane-active antifungal compound from Selaginella tamariscina. Choi, Y; Lee, DG; Lee, J; Woo, ER, 2009) | 3.24 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (1)
Inhibition Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Amyloid-beta precursor protein | Homo sapiens (human) | IC50 (µMol) | 50.0000 | 0.0005 | 3.8895 | 10.0000 | AID1591400 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (79)
Molecular Functions (13)
Ceullar Components (41)
Bioassays (2)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1233379 | Neuroprotective activity against 0.1 uM amyloid beta 42-induced toxicity in rat PC12 cells assessed as cell viability at 10 uM after 24 hrs by MTT assay | 2015 | Bioorganic & medicinal chemistry letters, Jul-15, Volume: 25, Issue:14 | Inhibitory activities of biflavonoids against amyloid-β peptide 42 cytotoxicity in PC-12 cells. |
| AID1591400 | Inhibition of human amyloid beta (1 to 40) assessed as reduction in aggregation measured after 24 hrs by ThT fluorescence assay | 2019 | Bioorganic & medicinal chemistry letters, 08-01, Volume: 29, Issue:15 | Naturally occurring biflavonoids with amyloid β aggregation inhibitory activity for development of anti-Alzheimer agents. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.84
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.84) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||